Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Molecular Cancer logoLink to Molecular Cancer
. 2019 Aug 6;18:122. doi: 10.1186/s12943-019-1051-x

Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer

Zhuo-yuan Lin 1,2,#, Guo Chen 1,#, Yan-qiong Zhang 3,7,8,#, Hui-chan He 1,#, Yu-xiang Liang 1, Jian-heng Ye 1,7,8, Ying-ke Liang 1,4, Ru-jun Mo 1,4, Jian-ming Lu 1,4, Yang-jia Zhuo 1,4, Yu Zheng 2,4, Fu-neng Jiang 1, Zhao-dong Han 1, Shu-lin Wu 7,8, Wei-de Zhong 1,4,5,6,, Chin-Lee Wu 1,7,8,
PMCID: PMC6683342  PMID: 31387585

Correction to: Mol Cancer (2017) 16:48

https://doi.org/10.1186/s12943-017-0615-x

After publication of the article [1], the author reported that this article contained some errors.

The photograph of sh-NC in Fig. 1c was misplaced. The correct version of the figure and the figure legend is presented below.

Fig. 1.

Fig. 1

Prognostic value of miR-30d expression in PCa patients and its functions on tumor growth and angiogenesis in vivo using LNCaP cell induced tumor xenografts. a Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival and overall survival of PCa patients based on miR- 30d expression in Taylor and TCGA datasets. b LNCaP cells stably expressing miR-30d formed significantly larger tumor nodules and remarkably speeded up tumor xenografts growth compared with the controls. Conversely, PCa cells that permanently suppressed miR-30d expression led to the smaller tumor nodules and the slower tumor growth compared with the control. c Immunohistochemical analysis using pan-endothelial marker CD31 antibody. d VEGFA protein expression in different groups detected by Western blot analysis. Data were presented as Mean ± SD. *P < 0.05. **P < 0.01

Contributor Information

Wei-de Zhong, Email: zhongwd2009@live.cn.

Chin-Lee Wu, Email: cwu2@mgh.harvard.edu.

Reference

  • 1.Lin Z-y, Chen G, Zhang Y-q, He H-c, Liang Y-x, Ye J-h, Liang Y-k, Mo R-j, Jian-ming L, Zhuo Y-j, Zheng Y, Jiang F-n, Han Z-d, Shu-lin W, Zhong W-d, Chin-Lee W. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;16:48. doi: 10.1186/s12943-017-0615-x. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

Articles from Molecular Cancer are provided here courtesy of BMC

RESOURCES